adenine and Recrudescence studies

Research Excerpts

Excerpt	Relevance	Reference
"We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies."	9.34	A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anagnostopoulos, A; Briso, EM; Cascavilla, N; Dobkowska, E; García Sanz, R; Hajek, R; Hauns, B; Lee, Y; Martin Sánchez, J; Oriol, A; Ozcan, M; Pour, L; Špička, I; Terjung, A, 2020)
"The activity of amonafide, a benzisoquinoline-1,3-dione, was assessed in 15 patients with advanced or recurrent sarcoma (11 previously treated)."	9.07	Phase II study of amonafide in advanced and recurrent sarcoma patients. ( Comis, RL; Nash, SL; O'Dwyer, PJ; Ozols, RF; Perez, RP, 1992)
"In this study, a tenofovir disoproxil fumarate (TDF) + hepatitis B immunoglobulin (HBIG) regimen was compared with lamivudine (LAM) + HBIG to determine the efficacy and safety of TDF in the prevention of hepatitis B virus (HBV) recurrence following liver transplantation (LT)."	7.80	The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation. ( Akarsu, M; Astarcıoğlu, İ; Hakim, GD; Karademir, S; Unek, T, 2014)
"Adefovir is usually applied for therapy of chronic hepatitis B (CHB), but its effectiveness after cessation is still unknown."	7.78	A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. ( Diao, S; Ha, M; Huang, C; Huang, Z; Kuan, C; Lin, M; She, H; Shen, L; Shen, W; Sun, L; Zhang, G, 2012)
"We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance."	7.77	Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. ( Byun, KS; Jung, ES; Jung, YK; Kim, JH; Lee, KG; Ryu, HS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ, 2011)
"It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection, but also in lamivudine-resistant (LAMV-R) cases."	7.75	[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients]. ( Choi, MS; Jung, HW; Kim, KH; Koh, KC; Lee, JH; Paik, SW; Park, SH; Yeon, KK; Yoo, BC, 2009)
"The most frequently used therapy for post-transplantation recurrence of hepatitis B virus (HBV) infection is lamivudine, but this drug is associated with a high resistance rate due to YMDD mutant."	7.74	Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. ( Cai, CJ; Chen, GH; Jiang, H; Jiang, N; Li, H; Li, X; Lu, MQ; Wang, GS; Xu, C; Yang, Y; Yi, HM; Yi, SH; Zhang, J; Zhang, JF; Zhang, Q; Zhang, YC, 2007)
"Treatment of post-transplantation recurrence of hepatitis B virus (HBV) infection despite prophylaxis with hepatitis B immunoglobulin (HBIG) and lamivudine combination therapy is not easy."	7.74	Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. ( Akyildiz, M; Aydin, U; Karasu, Z; Kilic, M; Ozacar, T; Zeytunlu, M, 2007)
"We report a patient whose cryoglobulinemic vasculitis recurred due to reactivation of lamivudine-resistant HBV."	7.73	Successful treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations. ( Cakir, N; Midilli, K; Pamuk, ON; Umit, H, 2006)
"The disease relapsed in 14 hepatitis B patients with decompensated liver cirrhosis during lamivudine treatment due to the YMDD motif mutation."	7.73	[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005)
"ADV is an effective rescue therapy for patients with lamivudine-resistant hepatitis B post-liver transplant."	7.72	Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. ( Da Costa, M; Dan, YY; Isaac, J; Lee, HL; Lee, KH; Lee, YM; Lim, SG; Mak, K; Prabhakaran, K; Sutedja, DS; Wai, CT; Wee, A, 2004)
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis."	7.72	Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003)
"Failure of prophylaxis for hepatitis B virus (HBV) recurrence in liver transplant patients with HBV immunoglobulin (HBIG) or lamivudine or both can be associated with rapid development of liver failure."	7.72	Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. ( Akay, S; Akyildiz, M; Karasu, Z; Tokat, Y, 2004)
"The identification of a second mutation in the cationic trypsinogen gene (HP2) suggests a dominant role of trypsin in premature protease activation-mediated forms of acute pancreatitis."	7.69	Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. ( Aston, CE; Ehrlich, GD; Furey, W; Gabbaizedeh, D; Gates, LK; Gorry, MC; Preston, RA; Ulrich, C; Whitcomb, DC; Zhang, Y, 1997)
"We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies."	5.34	A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anagnostopoulos, A; Briso, EM; Cascavilla, N; Dobkowska, E; García Sanz, R; Hajek, R; Hauns, B; Lee, Y; Martin Sánchez, J; Oriol, A; Ozcan, M; Pour, L; Špička, I; Terjung, A, 2020)
" Our results confirm the efficacy and safety of adefovir treatment in post-liver transplantation patients with lamivudine-resistant HBV, neither were adefovir-resistant mutations identified in patients after 21 months of therapy, nor were there adverse events, especially renal toxicity."	5.33	Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. ( Avilés, JF; Bárcena, R; Barrios, C; Buti, M; Casanovas, T; Cuervas, V; De la Mata, M; Del Campo, S; Delgado, M; Dieguez, ML; Fraga, E; Gonzalez, A; Herrero, JI; Loinaz, C; Mas, A; Moraleda, G; Moreno, JM; Muñoz, R; Otero, A; Prieto, M; Rueda, M; Sousa, JM, 2005)
"Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients."	5.32	Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003)
"The activity of amonafide, a benzisoquinoline-1,3-dione, was assessed in 15 patients with advanced or recurrent sarcoma (11 previously treated)."	5.07	Phase II study of amonafide in advanced and recurrent sarcoma patients. ( Comis, RL; Nash, SL; O'Dwyer, PJ; Ozols, RF; Perez, RP, 1992)
"Antiviral therapy using newer nucleos(t)ide analogues with lower resistance rates such as entecavir or tenofovir could suppress hepatitis B virus (HBV) replication, improve liver function, delay or obviate the need for liver transplantation in some patients, and reduce the risk of HBV recurrence."	4.90	Prevention of hepatitis B virus reinfection in liver transplant recipients. ( Roche, B; Samuel, D, 2014)
" Chronic hepatitis C can be treated preferably with a combination therapy (pegylated interferons + Ribavirin)."	4.82	[Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. ( Maier, KP, 2003)
"This retrospective study included 289 chronic hepatitis B (CHB) patients without cirrhosis who received entecavir (n = 93), TDF (n = 103), or TAF (n = 86) retreatment for at least 12 months after entecavir or TDF cessation."	4.31	Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. ( Chang, KC; Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Lu, SN; Wang, JH, 2023)
"Adenine phosphoribosyltransferase (APRT) deficiency is a hereditary purine metabolism disorder that causes kidney stones and chronic kidney disease (CKD)."	3.91	Long-term renal outcomes of APRT deficiency presenting in childhood. ( Agustsdottir, IM; Edvardsson, VO; Indridason, OS; Palsson, R; Runolfsdottir, HL, 2019)
"We investigated the durability of virological response after lamivudine (LAM) discontinuation in LAM-resistant chronic hepatitis B (CHB) patients with complete virological response after LAM-adefovir (ADV) combination therapy."	3.85	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Park, JY, 2017)
"Low-dose hepatitis B immunoglobulin (HBIG) and nucleos(t)ides analogs (lamivudine/adefovir) used for the prevention of hepatitis B virus (HBV) recurrence after liver transplantation (LT) are associated with some risk of HBV recurrence and antiviral resistance."	3.81	Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis? ( Choudhary, NS; Goja, S; Menon, PB; Mohanka, R; Rastogi, A; Saigal, S; Saraf, N; Soin, AS, 2015)
" Three of the 12 patients who were treated with combination therapy group were carriers of YMDD mutants and all three showed improvement in liver function and hepatic histology after receiving adefovir dipivoxil,instead of lamivudine,in the early stage of recurrent hepatitis B after OLT."	3.80	[Clinical pathology of recurrent hepatitis B after liver transplantation]. ( Jiao, Z; Yan, L; Zhang, D, 2014)
"In this study, a tenofovir disoproxil fumarate (TDF) + hepatitis B immunoglobulin (HBIG) regimen was compared with lamivudine (LAM) + HBIG to determine the efficacy and safety of TDF in the prevention of hepatitis B virus (HBV) recurrence following liver transplantation (LT)."	3.80	The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation. ( Akarsu, M; Astarcıoğlu, İ; Hakim, GD; Karademir, S; Unek, T, 2014)
"Adefovir is usually applied for therapy of chronic hepatitis B (CHB), but its effectiveness after cessation is still unknown."	3.78	A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. ( Diao, S; Ha, M; Huang, C; Huang, Z; Kuan, C; Lin, M; She, H; Shen, L; Shen, W; Sun, L; Zhang, G, 2012)
"We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance."	3.77	Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. ( Byun, KS; Jung, ES; Jung, YK; Kim, JH; Lee, KG; Ryu, HS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ, 2011)
"Chronic hepatitis B patients who were treated with anti-viral agents (lamivudine, adefovir, entecavir) and have stopped the treatment were recruited."	3.77	Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. ( Chan, HL; Ge, S; Guo, W; Hu, J; Huang, X; Jiang, J; Jiang, Z; Liang, Y; Liu, Z; Su, M; Wong, VW; Xie, R; Zhu, M, 2011)
"It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection, but also in lamivudine-resistant (LAMV-R) cases."	3.75	[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients]. ( Choi, MS; Jung, HW; Kim, KH; Koh, KC; Lee, JH; Paik, SW; Park, SH; Yeon, KK; Yoo, BC, 2009)
"Treatment of post-transplantation recurrence of hepatitis B virus (HBV) infection despite prophylaxis with hepatitis B immunoglobulin (HBIG) and lamivudine combination therapy is not easy."	3.74	Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. ( Akyildiz, M; Aydin, U; Karasu, Z; Kilic, M; Ozacar, T; Zeytunlu, M, 2007)
"The most frequently used therapy for post-transplantation recurrence of hepatitis B virus (HBV) infection is lamivudine, but this drug is associated with a high resistance rate due to YMDD mutant."	3.74	Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. ( Cai, CJ; Chen, GH; Jiang, H; Jiang, N; Li, H; Li, X; Lu, MQ; Wang, GS; Xu, C; Yang, Y; Yi, HM; Yi, SH; Zhang, J; Zhang, JF; Zhang, Q; Zhang, YC, 2007)
"We report a patient whose cryoglobulinemic vasculitis recurred due to reactivation of lamivudine-resistant HBV."	3.73	Successful treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations. ( Cakir, N; Midilli, K; Pamuk, ON; Umit, H, 2006)
"Hepatitis B immunoglobulin with lamivudine prophylaxis (LAM/HBIG) is effective in preventing Hepatitis B (HBV) recurrence posttransplant but is expensive and inconvenient."	3.73	Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. ( Dan, YY; Lim, SG; Wai, CT; Yeoh, KG, 2006)
"One patient with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 15 months of treatment."	3.73	Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. ( Lai, V; Mirza, D; Mutimer, D; Zhang, WX, 2006)
"The disease relapsed in 14 hepatitis B patients with decompensated liver cirrhosis during lamivudine treatment due to the YMDD motif mutation."	3.73	[Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation]. ( Su, GG; Ying, MF; Zhao, NF; Zhou, Y, 2005)
"ADV is an effective rescue therapy for patients with lamivudine-resistant hepatitis B post-liver transplant."	3.72	Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. ( Da Costa, M; Dan, YY; Isaac, J; Lee, HL; Lee, KH; Lee, YM; Lim, SG; Mak, K; Prabhakaran, K; Sutedja, DS; Wai, CT; Wee, A, 2004)
"Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM)."	3.72	Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. ( De Medina, M; Madariaga, J; Montalbano, M; Neff, GW; Nery, C; Nery, J; O'brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, N; Tzakis, AG, 2004)
"Failure of prophylaxis for hepatitis B virus (HBV) recurrence in liver transplant patients with HBV immunoglobulin (HBIG) or lamivudine or both can be associated with rapid development of liver failure."	3.72	Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. ( Akay, S; Akyildiz, M; Karasu, Z; Tokat, Y, 2004)
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis."	3.72	Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003)
" Lamivudine is safe and effective in liver transplant recipients with recurrent hepatitis B virus (HBV) infection caused by wild-type virus or failure of hepatitis B immunoglobulin therapy."	3.71	Treatment of recurrent hepatitis B infection in liver transplant recipients. ( Terrault, NA, 2002)
"The identification of a second mutation in the cationic trypsinogen gene (HP2) suggests a dominant role of trypsin in premature protease activation-mediated forms of acute pancreatitis."	3.69	Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. ( Aston, CE; Ehrlich, GD; Furey, W; Gabbaizedeh, D; Gates, LK; Gorry, MC; Preston, RA; Ulrich, C; Whitcomb, DC; Zhang, Y, 1997)
" The primary objective of part A (dose escalation) was to assess the safety of daily oral ibrutinib (420 mg or 560 mg) in combination with intravenous nivolumab (3 mg/kg every 2 weeks) to ascertain a recommended phase 2 dose in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma."	2.90	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. ( Alvarez, J; Avivi, I; Balasubramanian, S; Ben-Yehuda, D; Bosch, F; Brody, J; Buglio, D; Caballero Barrigón, MD; Carpio, C; Ceulemans, R; Cordoba, R; de Jong, J; Demirkan, F; Ferhanoglu, B; Fourneau, N; Hellmann, A; Hodkinson, BP; Horowitz, NA; Jurczak, W; Kuss, B; Lopez-Guillermo, A; Ma, DDF; Marlton, P; Nagler, A; Ozcan, M; Schaffer, M; Streit, M; Wang, SS; Wrobel, T; Yağci, M; Younes, A, 2019)
"The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax)."	2.90	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. ( Bishop, R; Bloor, A; Boucher, R; Brock, K; Devereux, S; Fegan, C; Forconi, F; Fox, CP; Gribben, JG; Hillmen, P; MacDonald, D; McCaig, A; Munir, T; Muñoz-Vicente, S; Patten, PEM; Pettitt, A; Rawstron, AC; Schuh, A; Yates, FJ, 2019)
" Cohort 1 (n = 3) consisted of two phases, a single-dose (140 and 280 mg) phase and a multiple-dose (420 mg) phase of ibrutinib; cohort 2 (n = 6) included multiple doses of ibrutinib 560 mg; and cohort 3 (n = 6) included only patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) dosed at ibrutinib 420 mg."	2.82	Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. ( Aoki, T; Ishizawa, K; Morishita, T; Munakata, W; Ogura, M; Suzuki, T; Takahara, S; Tobinai, K; Uchida, T; Ushijima, Y, 2016)
"Ibrutinib combined with rituximab is active and well tolerated in patients with relapsed or refractory mantle cell lymphoma."	2.82	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. ( Addison, A; Badillo, M; Champlin, R; Chen, W; Chuang, H; DeLa Rosa, M; Fayad, L; Hagemeister, F; Lam, L; Lee, H; Li, S; Medeiros, LJ; Nomie, K; Oki, Y; Romaguera, J; Samaniego, F; Santos, D; Turturro, F; Wagner-Bartak, N; Wang, ML; Westin, J; Young, KH; Zhang, H; Zhang, L; Zhao, D, 2016)
" A total of 8/16 patients (50%) had at least one grade 3 adverse event (AE), and 5 (31."	2.82	Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. ( Choi, I; Fukuhara, N; Hatake, K; Ishikawa, T; Kinoshita, T; Kitano, T; Maruyama, D; Matsuno, Y; Nagai, H; Nishikawa, T; Nishikori, M; Shibayama, H; Takahara, S; Tobinai, K; Uchida, T, 2016)
"The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions."	2.78	Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. ( Blum, KA; Buggy, JJ; Burger, JA; Byrd, JC; Chang, BY; Clow, F; Coleman, M; Coutre, SE; Flinn, IW; Furman, RR; Grant, B; Hedrick, E; Heerema, NA; James, DF; Johnson, AJ; Jones, JA; O'Brien, S; Sharman, JP; Sukbuntherng, J; Wierda, WG; Zhao, W, 2013)
"No patient experienced HBV recurrence through 72 weeks of the study while he or she was receiving the randomized treatment."	2.78	Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. ( Bzowej, N; Dinh, P; Flaherty, J; Martin, P; Poordad, F; Pungpapong, S; Rossi, S; Schiano, T; Spivey, J; Subramanian, GM; Teperman, LW, 2013)
"Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy."	2.55	Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. ( Bence-Bruckler, I; Coutre, S; Delage, R; Owen, CJ; Shustik, C; Toze, CL, 2017)
"Regardless of prophylaxis, the risk of recurrence is associated with pre-graft viral load."	2.43	[Liver transplantation for complications of hepatitis B]. ( Roche, B; Samuel, D, 2006)
"In the past, an unacceptable HBV recurrence rate with a high rate of graft loss was noted."	2.43	Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. ( Schiff, ER; Schreibman, IR, 2006)
"However, recurrence rates are high after cessation of treatment."	2.43	[Management of chronic hepatitis B]. ( von Weizsäcker, F, 2005)
"Lamivudine has been widely used in the management of HBV transplant patients."	2.42	Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. ( Burroughs, AK; Papatheodoridis, GV; Sevastianos, V, 2003)
"Furthermore, chronic hepatitis B was historically a controversial indication for liver transplantation because of a low post-transplant survival, with graft infection being the major contributor to adverse outcomes."	2.42	Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. ( Keeffe, EB; Yu, AS, 2003)
"In IFN-naive patients with chronic hepatitis B (and compensated liver disease) alpha-interferon is still the first-line therapy."	2.41	[New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?]. ( Erhardt, A; Häussinger, D; Heintges, T; Petry, W, 2000)
" Adverse events occurred in 74."	1.72	Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance. ( Akizuki, R; Fujino, A; Nomura, F; Omi, A; Tsujioka, S, 2022)
"Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse."	1.62	Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. ( Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR, 2021)
" Emerging real-world-data shows similar response and survival, but higher discontinuation rates due to adverse events (AEs)."	1.51	Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. ( Angelopoulou, M; Bitsani, C; Dimou, M; Iliakis, T; Kalyva, S; Koudouna, A; Kyrtsonis, MC; Panayiotidis, P; Papaioannou, P; Pardalis, V; Tsaftaridis, P; Vassilakopoulos, TP, 2019)
"Cancer recurrence after initial diagnosis and treatment is a major cause of breast cancer (BC) mortality, which results from the metastatic outbreak of dormant tumour cells."	1.48	Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. ( Green, JE; Hunter, KW; Nini, R; Vera-Ramirez, L; Vodnala, SK, 2018)
"Chylothorax is an unusual cause of pleural effusion, typically caused by trauma or malignancy."	1.46	Recurrent chylothorax: a clinical mystery. ( Dalal, B; Dogra, S; Meka, SG; Otoupalova, E, 2017)
"Lenalidomide-based treatment showed clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle cell lymphoma who previously failed ibrutinib therapy."	1.46	Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). ( Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M, 2017)
"The cumulative probability of HBV recurrence at 1, 3, 5, and 7 years was 1%, 3%, 3%, and 4%, respectively."	1.43	The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence. ( Akyildiz, M; Balci, D; Cinar, K; Dayangac, M; Gungor, G; Hazinedaroglu, S; Idilman, R; Kalkan, C; Keskin, O; Tokat, Y; Yilmaz, TU, 2016)
"Ninety-five consecutive patients (93 chronic lymphocytic leukemia, 2 small lymphocytic leukemia) were included in the study between May 2014 and May 2015."	1.43	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. ( Andersson, PO; Asklid, A; Hansson, L; Karlsson, C; Karlsson, K; Lauri, B; Lundin, J; Mattsson, M; Norin, S; Österborg, A; Sandstedt, A; Winqvist, M, 2016)
"Hepatitis B virus recurrence within 12 months was 4."	1.42	Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation. ( Choi, GH; Choi, JS; Joo, DJ; Ju, MK; Kim, MS; Kim, SI; Lee, J; Lee, JG; Lee, JJ; Song, SH, 2015)
"The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation."	1.40	Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. ( Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N, 2014)
"Patients with HBV recurrence were divided into four groups according to their treatment: group L (lamivudine-based therapy n = 21) and group N [new nucleos(t)ide analogue (NA)-based therapy, n = 38]."	1.39	Outcome of various treatments for posttransplant hepatitis B virus recurrence. ( Han, SS; Hong, G; Kong, SY; Lee, KB; Lee, KW; Park, KU; Park, SJ; Suh, KS; Yi, NJ, 2013)
"There was no mortality due to HBV recurrence."	1.39	Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. ( Goyal, N; Gupta, S; Kumar, A; Taneja, S; Wadhawan, M, 2013)
"Osteonecrosis of the jaw (ONJ) is a major complication associated with long-term use of bisphosphonates (BP)."	1.38	New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw. ( Balla, B; Kósa, JP; Lakatos, P; Lazáry, A; Nagy, Z; Podani, J; Takács, I; Tóbiás, B; Vaszilko, M, 2012)
"The median time to HBV recurrence after transplantation was 31."	1.38	[Prognosis analysis of hepatitis B virus recurrence after liver transplantation: a single-center study of 38 cases]. ( Deng, YL; Gao, W; Jiang, WT; Qu, W; Rao, W; Shen, ZY; Sun, LY; Sun, XY; Zhang, JJ; Zhang, YM; Zhu, ZJ, 2012)
" Recurrent aphthous stomatitis is a common ulcerative disease of the oral mucosa."	1.37	Association between recurrent aphthous stomatitis and inheritance of a single-nucleotide polymorphism of the NOS2 gene encoding inducible nitric oxide synthase. ( Darwazeh, AM; Hassan, AF; Karasneh, JA; Thornhill, M, 2011)
"Forty-five HBeAg-positive chronic hepatitis B patients with a virologic response [negative PCR (<12 IU/ml)] who had discontinued therapy were analyzed retrospectively for VR, HBeAg reversion and biochemical flare."	1.37	Defining virologic relapse in chronic hepatitis B. ( Cho, HC; Choi, MS; Gwak, GY; Kim, KH; Koh, KC; Lee, JH; Lee, YY; Paik, SW; Sinn, DH; Yoo, BC; Yun, WK, 2011)
"All three patients progressed to ESRD, within 1 month following renal biopsy in two and after 9 months in one."	1.36	Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. ( Boelkins, M; Broviac, J; Cornell, LD; Fidler, ME; Milliner, DS; Nasr, SH; Sethi, S, 2010)
" Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dosing schemes."	1.35	Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. ( Hadem, J; Hooman, N; Klempnauer, J; Manns, MP; Philipp, G; Priess, A; Rifai, K; Rosenau, J; Tillmann, HL; Vaske, B, 2008)
"We report a case of autoimmune thrombocytopenia associated with acute reverse seroconversion of hepatitis B in a patient who was initially hepatitis B virus surface antigen negative and hepatitis B virus surface antibody positive."	1.34	[Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation]. ( Aubourg, A; Bacq, Y; d'Alteroche, L; Gaudy, C; Senecal, D, 2007)
"Adefovir dipivoxil is a acyclic nucleotide phosphate analogue and known to have potent anti-HBV effect."	1.33	[Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report]. ( Ahn, CS; Ha, TY; Hwang, S; Kim, KH; Kim, KK; Lee, SG; Moon, DB, 2005)
" Our results confirm the efficacy and safety of adefovir treatment in post-liver transplantation patients with lamivudine-resistant HBV, neither were adefovir-resistant mutations identified in patients after 21 months of therapy, nor were there adverse events, especially renal toxicity."	1.33	Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. ( Avilés, JF; Bárcena, R; Barrios, C; Buti, M; Casanovas, T; Cuervas, V; De la Mata, M; Del Campo, S; Delgado, M; Dieguez, ML; Fraga, E; Gonzalez, A; Herrero, JI; Loinaz, C; Mas, A; Moraleda, G; Moreno, JM; Muñoz, R; Otero, A; Prieto, M; Rueda, M; Sousa, JM, 2005)
"Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients."	1.32	Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003)
"This is the first report of recurrence of the microcrystalline nephritis in a kidney transplant with subsequent loss of allograft function."	1.29	Chronic renal failure secondary to 2,8-dihydroxyadenine deposition: the first report of recurrence in a kidney transplant. ( Daudon, M; Deland, E; Gagné, ER; Nawar, T; Noël, LH, 1994)

Research

Studies (159)

Authors

Clinical Trials (31)

Trial Overview

Trial Outcomes

Complete Response Rate

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.63)	18.7374
1990's	8 (5.03)	18.2507
2000's	35 (22.01)	29.6817
2010's	96 (60.38)	24.3611
2020's	19 (11.95)	2.80

Authors	Studies
Balasubramanian, S	4
Hodkinson, B	1
Schuster, SJ	5
Fowler, NH	2
Trotman, J	2
Hess, G	4
Cheson, BD	3
Schaffer, M	3
Sun, S	3
Deshpande, S	2
Vermeulen, J	4
Salles, G	2
Gopal, AK	3
Omi, A	1
Nomura, F	1
Tsujioka, S	1
Fujino, A	1
Akizuki, R	1
Chiu, SM	1
Chang, KC	1
Hu, TH	2
Hung, CH	2
Wang, JH	2
Lu, SN	2
Chen, CH	3
Jeng, WJ	1
Liu, YC	1
Chien, RN	1
Yang, S	3
Li, N	2
Zhu, R	1
Feng, Y	1
Zhuo, J	1
Gale, RP	1
Huang, X	5
Nierengarten, MB	1
Carriles, C	1
Ordóñez-Fernández, L	1
Arias-Martínez, A	1
Menárguez-Blanc, R	1
Rosado-María, MC	1
Eichhorst, B	2
Fürstenau, M	1
Hallek, M	2
Hajek, R	1
Pour, L	1
Ozcan, M	2
Martin Sánchez, J	1
García Sanz, R	1
Anagnostopoulos, A	1
Oriol, A	1
Cascavilla, N	1
Terjung, A	1
Lee, Y	1
Briso, EM	1
Dobkowska, E	1
Hauns, B	1
Špička, I	1
Huang, SJ	1
Gerrie, AS	1
Young, S	1
Tucker, T	1
Bruyere, H	1
Hrynchak, M	1
Galbraith, P	1
Al Tourah, AJ	1
Dueck, G	1
Noble, MC	1
Ramadan, KM	1
Tsang, P	1
Hardy, E	1
Sehn, L	1
Toze, CL	2
Sugimoto, S	1
Shingu, Y	1
Doenst, T	1
Yamakawa, T	1
Asai, H	1
Wakasa, S	1
Matsui, Y	1
Halim, AA	1
Alsayed, B	1
Embarak, S	1
Yaseen, T	1
Dabbous, S	1
Fontaine, O	1
Dueluzeau, R	1
Raibaud, P	1
Chabanet, C	1
Popoff, MR	1
Badoual, J	1
Gabilan, JC	1
Andremont, A	1
Gómez, L	1
Andrés, S	1
Sánchez, J	1
Alonso, JM	1
Rey, J	1
López, F	1
Jiménez, A	1
Yan, Z	1
Zhou, L	1
Zhao, Y	3
Wang, J	8
Huang, L	2
Hu, K	1
Liu, H	4
Wang, H	4
Guo, Z	1
Song, Y	1
Huang, H	4
Yang, R	1
Owen, TW	1
Al-Kaysi, RO	1
Bardeen, CJ	1
Cheng, Q	1
Wu, S	1
Cheng, T	1
Zhou, X	1
Wang, B	4
Zhang, Q	6
Wu, X	3
Yao, Y	3
Ochiai, T	1
Ishiguro, H	2
Nakano, R	2
Kubota, Y	2
Hara, M	1
Sunada, K	1
Hashimoto, K	1
Kajioka, J	1
Fujishima, A	1
Jiao, J	3
Gai, QY	3
Wang, W	2
Zang, YP	2
Niu, LL	2
Fu, YJ	3
Wang, X	4
Yao, LP	1
Qin, QP	1
Wang, ZY	1
Liu, J	4
Aleksic Sabo, V	1
Knezevic, P	1
Borges-Argáez, R	1
Chan-Balan, R	1
Cetina-Montejo, L	1
Ayora-Talavera, G	1
Sansores-Peraza, P	1
Gómez-Carballo, J	1
Cáceres-Farfán, M	1
Jang, J	1
Akin, D	1
Bashir, R	1
Yu, Z	1
Zhu, J	2
Jiang, H	2
He, C	2
Xiao, Z	1
Xu, J	2
Sun, Q	1
Han, D	1
Lei, H	1
Zhao, K	2
Zhu, L	1
Li, X	5
Fu, H	2
Wilson, BK	1
Step, DL	1
Maxwell, CL	1
Gifford, CA	1
Richards, CJ	1
Krehbiel, CR	1
Warner, JM	1
Doerr, AJ	1
Erickson, GE	1
Guretzky, JA	1
Rasby, RJ	1
Watson, AK	1
Klopfenstein, TJ	1
Sun, Y	4
Liu, Z	4
Pham, TD	1
Lee, BK	1
Yang, FC	1
Wu, KH	1
Lin, WP	1
Hu, MK	1
Lin, L	3
Shao, J	1
Sun, M	1
Xu, G	2
Zhang, X	6
Xu, N	1
Wang, R	1
Liu, S	1
He, H	1
Dong, X	2
Yang, M	2
Yang, Q	1
Duan, S	1
Yu, Y	2
Han, J	2
Zhang, C	3
Chen, L	3
Yang, X	1
Li, W	3
Wang, T	2
Campbell, DA	1
Gao, K	1
Zager, RA	1
Johnson, ACM	1
Guillem, A	1
Keyser, J	1
Singh, B	1
Steubl, D	1
Schneider, MP	1
Meiselbach, H	1
Nadal, J	1
Schmid, MC	1
Saritas, T	1
Krane, V	1
Sommerer, C	1
Baid-Agrawal, S	1
Voelkl, J	1
Kotsis, F	1
Köttgen, A	1
Eckardt, KU	1
Scherberich, JE	1
Li, H	5
Yao, L	2
Sun, L	4
Zhu, Z	1
Naren, N	1
Zhang, XX	2
Gentile, GL	1
Rupert, AS	1
Carrasco, LI	1
Garcia, EM	1
Kumar, NG	1
Walsh, SW	1
Jefferson, KK	1
Guest, RL	1
Samé Guerra, D	1
Wissler, M	1
Grimm, J	1
Silhavy, TJ	1
Lee, JH	4
Yoo, JS	1
Kim, Y	1
Kim, JS	2
Lee, EJ	1
Roe, JH	1
Delorme, M	1
Bouchard, PA	1
Simon, M	1
Simard, S	1
Lellouche, F	1
D'Urzo, KA	1
Mok, F	1
D'Urzo, AD	1
Koneru, B	1
Lopez, G	1
Farooqi, A	1
Conkrite, KL	1
Nguyen, TH	1
Macha, SJ	1
Modi, A	1
Rokita, JL	1
Urias, E	1
Hindle, A	1
Davidson, H	1
Mccoy, K	1
Nance, J	1
Yazdani, V	1
Irwin, MS	1
Wheeler, DA	1
Maris, JM	1
Diskin, SJ	1
Reynolds, CP	1
Abhilash, L	1
Kalliyil, A	1
Sheeba, V	1
Hartley, AM	2
Meunier, B	2
Pinotsis, N	1
Maréchal, A	2
Xu, JY	1
Genko, N	1
Haraux, F	1
Rich, PR	1
Kamalanathan, M	1
Doyle, SM	1
Xu, C	2
Achberger, AM	1
Wade, TL	1
Schwehr, K	1
Santschi, PH	1
Sylvan, JB	1
Quigg, A	1
Leong, W	1
Xu, W	2
Gao, S	1
Zhai, X	1
Wang, C	2
Gilson, E	1
Ye, J	1
Lu, Y	1
Yan, R	1
Zhang, Y	8
Hu, Z	1
You, Q	1
Cai, Q	1
Yang, D	1
Gu, S	1
Dai, H	1
Zhao, X	1
Gui, C	1
Gui, J	1
Wu, PK	1
Hong, SK	1
Starenki, D	1
Oshima, K	1
Shao, H	1
Gestwicki, JE	1
Tsai, S	1
Park, JI	1
Wang, Y	7
Zhao, R	1
Gu, Z	1
Dong, C	2
Guo, G	1
Li, L	5
Barrett, HE	1
Meester, EJ	1
van Gaalen, K	1
van der Heiden, K	1
Krenning, BJ	1
Beekman, FJ	1
de Blois, E	1
de Swart, J	1
Verhagen, HJ	1
Maina, T	1
Nock, BA	1
Norenberg, JP	1
de Jong, M	1
Gijsen, FJH	1
Bernsen, MR	1
Martínez-Milla, J	1
Galán-Arriola, C	1
Carnero, M	1
Cobiella, J	1
Pérez-Camargo, D	1
Bautista-Hernández, V	1
Rigol, M	1
Solanes, N	1
Villena-Gutierrez, R	1
Lobo, M	1
Mateo, J	1
Vilchez-Tschischke, JP	1
Salinas, B	1
Cussó, L	1
López, GJ	1
Fuster, V	1
Desco, M	1
Sanchez-González, J	1
Ibanez, B	1
van den Berg, P	1
Schweitzer, DH	1
van Haard, PMM	1
Geusens, PP	1
van den Bergh, JP	1
Zhu, X	2
Xu, H	3
Yang, G	2
Lin, Z	1
Salem, HF	1
Nafady, MM	1
Kharshoum, RM	1
Abd El-Ghafar, OA	1
Farouk, HO	1
Domiciano, D	1
Nery, FC	1
de Carvalho, PA	1
Prudente, DO	1
de Souza, LB	1
Chalfun-Júnior, A	1
Paiva, R	1
Marchiori, PER	1
Lu, M	2
An, Z	1
Jiang, J	3
Li, J	9
Du, S	1
Zhou, H	1
Cui, J	1
Wu, W	1
Liu, Y	7
Song, J	1
Lian, Q	1
Uddin Ahmad, Z	1
Gang, DD	1
Konggidinata, MI	1
Gallo, AA	1
Zappi, ME	1
Yang, TWW	1
Johari, Y	1
Burton, PR	1
Earnest, A	1
Shaw, K	1
Hare, JL	1
Brown, WA	1
Kim, GA	1
Han, S	1
Choi, GH	2
Choi, J	1
Lim, YS	1
Gallo, A	1
Cancelli, C	1
Ceron, E	1
Covino, M	1
Capoluongo, E	1
Pocino, K	1
Ianiro, G	1
Cammarota, G	1
Gasbarrini, A	1
Montalto, M	1
Somasundar, Y	1
Lu, IC	1
Mills, MR	1
Qian, LY	1
Olivares, X	1
Ryabov, AD	1
Collins, TJ	1
Zhao, L	1
Doddipatla, S	1
Thomas, AM	1
Nikolayev, AA	1
Galimova, GR	1
Azyazov, VN	1
Mebel, AM	1
Kaiser, RI	1
Guo, S	1
Yang, P	1
Yu, X	2
Wu, Y	2
Zhang, H	4
Yu, B	2
Han, B	1
George, MW	1
Moor, MB	1
Bonny, O	1
Langenberg, E	1
Paik, H	1
Smith, EH	1
Nair, HP	1
Hanke, I	1
Ganschow, S	1
Catalan, G	1
Domingo, N	1
Schlom, DG	1
Assefa, MK	1
Wu, G	2
Hayton, TW	1
Becker, B	1
Enikeev, D	1
Netsch, C	1
Gross, AJ	1
Laukhtina, E	1
Glybochko, P	1
Rapoport, L	1
Herrmann, TRW	1
Taratkin, M	1
Dai, W	1
Shi, J	2
Carreno, J	1
Kloner, RA	1
Pickersgill, NA	1
Vetter, JM	1
Kim, EH	1
Cope, SJ	1
Du, K	1
Venkatesh, R	1
Giardina, JD	1
Saad, NES	1
Bhayani, SB	1
Figenshau, RS	1
Eriksson, J	1
Landfeldt, E	1
Ireland, S	1
Jackson, C	1
Wyatt, E	1
Gaudig, M	1
Stancill, JS	1
Happ, JT	1
Broniowska, KA	1
Hogg, N	1
Corbett, JA	1
Tang, LF	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma[NCT01779791]	Phase 2	110 participants (Actual)	Interventional	2013-04-17	Completed
A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations[NCT03226301]	Phase 2	230 participants (Anticipated)	Interventional	2017-06-23	Active, not recruiting
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)[NCT02332980]	Phase 2	65 participants (Actual)	Interventional	2015-02-19	Completed
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.[NCT02341781]		30 participants (Actual)	Observational	2015-04-30	Completed
A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma[NCT02460276]	Phase 2	50 participants (Actual)	Interventional	2015-04-30	Completed
A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma[NCT05014100]	Phase 2	55 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
A Phase I Study of Lenalidomide in Combination With Rituximab and Ibrutinib in Relapsed and Refractory CLL and SLL[NCT02200848]	Phase 1	5 participants (Actual)	Interventional	2014-04-30	Terminated (stopped due to Recruitment difficulties and toxicity)
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy[NCT02427620]	Phase 2	131 participants (Anticipated)	Interventional	2015-06-03	Active, not recruiting
Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b[NCT02883647]		100 participants (Anticipated)	Observational	2014-01-31	Recruiting
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies[NCT02329847]	Phase 1/Phase 2	144 participants (Actual)	Interventional	2015-03-11	Completed
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma[NCT03478514]	Phase 2	39 participants (Actual)	Interventional	2018-09-11	Active, not recruiting
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)[NCT03136497]	Phase 1	10 participants (Actual)	Interventional	2017-09-05	Active, not recruiting
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2019-04-11	Terminated (stopped due to Insufficient accrual)
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma[NCT01236391]	Phase 2	115 participants (Actual)	Interventional	2011-02-28	Completed
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236]	Phase 1	27 participants (Actual)	Interventional	2015-06-18	Active, not recruiting
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]	Phase 1/Phase 2	133 participants (Actual)	Interventional	2010-05-31	Completed
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]	Phase 3	22 participants (Actual)	Interventional	2019-12-09	Active, not recruiting
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707]	Phase 3	391 participants (Actual)	Interventional	2012-06-30	Completed
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]		40 participants (Actual)	Observational [Patient Registry]	2018-12-01	Completed
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947]	Phase 2	3 participants (Actual)	Interventional	2018-12-01	Completed
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895]		40 participants (Actual)	Observational	2017-07-21	Active, not recruiting
Expression of CD19 Complex in Lymphoproliferative Disorders[NCT04734470]		92 participants (Anticipated)	Observational	2021-03-31	Not yet recruiting
Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097]	Phase 2	15 participants (Anticipated)	Interventional	2022-10-30	Not yet recruiting
An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia[NCT01217749]	Phase 1/Phase 2	71 participants (Actual)	Interventional	2010-12-31	Completed
A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)[NCT01589302]	Phase 2	154 participants (Actual)	Interventional	2012-05-21	Active, not recruiting
A Phase 1 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Subjects With Recurrent Mature B-Cell Neoplasms[NCT01704963]	Phase 1	15 participants (Actual)	Interventional	2012-09-12	Completed
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL[NCT01880567]	Phase 2	113 participants (Actual)	Interventional	2013-07-15	Active, not recruiting
A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy[NCT01646021]	Phase 3	280 participants (Actual)	Interventional	2012-12-10	Completed
A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02169180]	Phase 2	16 participants (Actual)	Interventional	2014-08-31	Completed
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628]	Phase 2	63 participants (Actual)	Interventional	2013-12-31	Completed
An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy[NCT02068365]	Phase 4	41 participants (Actual)	Interventional	2013-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Will be defined as complete response or incomplete blood count recovery. Estimated by the number of patients who achieve an incomplete blood count recovery or complete response divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true complete response rate will be calculated in each arm. (NCT02332980)
Timeframe: 1 year

Confirmed All Response Rate of Patients Treated With Combination Therapy

Intervention	proportion of participants (Number)
Arm A (CLL)	0.0400
Arm B (NHL)	0
Arm C (CLL With Richters)	0
Arm A (Continuation Phase)	0.4000
Arm C (Continuation Phase)	0

Confirmed response rate will be estimated by the number of patients with an objective status of complete response, incomplete blood count recovery, nodular partial response, clinical complete response or partial response while on the combination therapy divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate to the combination will be calculated. In addition, the responders on this study will be further examined in an exploratory manner to determine if there are any patterns in prognostic factors or disease characteristics, including whether the patient had a Richter's transformation or ibrutinib-resistant disease, for both single agent pembrolizumab and combination therapy responders. (NCT02332980)
Timeframe: 1 year

Duration of Response

Intervention	proportion of participants (Number)
Arm A (Continuation Phase)	0.6000
Arm C (Continuation Phase)	0.1538

The distribution of duration of response will be estimated using the method of Kaplan-Meier. Duration of response (DR) is defined for all evaluable patients who have achieved a PR, nPR, CCR, CRi, or CR (Arms A and B) or PMR, CMR, PR or CR (Arm C) as the date at which the patient's objective status is first noted to be a PR, nPR, CCR, CRi, or CR (Arms A and B) or PMR, CMR, PR or CR (Arm C) to the earliest date relapse is documented. (NCT02332980)
Timeframe: 5 years

Incidence of Adverse Events

Intervention	Months (Median)
Arm A (CLL)	6.9
Arm A (Continuation Phase)	5.9
Arm C (Continuation Phase)	NA

Will be measured per National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Adverse events will be evaluated for single-agent pembrolizumab in each arm and also for the combination of pembrolizumab and the signal inhibitor in Arm A and Arm C. This outcome is reported in the adverse events section of this report. (NCT02332980)
Timeframe: 1 year

Overall Survival

Intervention	Participants (Count of Participants)
Arm A (CLL)	25
Arm B (NHL)	23
Arm C (CLL With Richters)	17
Arm A (Continuation Phase)	5
Arm C (Continuation Phase)	13

The distribution of overall survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

Progression-free Survival of Patients Treated in Single Agent Phase

Intervention	Months (Median)
Arm A (CLL)	10.6
Arm B (NHL)	48.6
Arm C (CLL With Richters)	11.5
Arm A (Continuation Phase)	11.7
Arm C (Continuation Phase)	13.3

The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT02332980)
Timeframe: 5 years

Progression-free Survival of Patients Treated With Combination Therapy

Intervention	Months (Median)
Arm A (CLL)	2.8
Arm B (NHL)	4.2
Arm C (CLL With Richters)	2.2

The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT02332980)
Timeframe: 5 years

Proportion of Patients Who Achieve a Confirmed Response

Intervention	Months (Median)
Arm A (Continuation Phase)	7.6
Arm C (Continuation Phase)	5.4

Confirmed response is defined to be a partial response, nodular partial response, clinical complete response, confirmed response with incomplete blood count recovery or confirmed response (Arm A and B), or complete metabolic response, partial metabolic response, partial response, or confirmed response (Arm C). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial confidence intervals for the true success proportion will be calculated. (NCT02332980)
Timeframe: 1 year

Time to Next Treatment for Patients on Combination Therapy

Intervention	proportion of responders (Number)
Arm A (CLL)	0.0800
Arm B (NHL)	0
Arm C (CLL With Richters)	0

The distribution of time to next treatment will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

Time to Next Treatment for Patients Treated With Single-agent Pembrolizumab

Intervention	Months (Median)
Arm A (Continuation Phase)	7.7
Arm C (Continuation Phase)	3.2

The distribution of time to next treatment will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

Treatment-free Survival of Patients Treated With Combination Therapy

Intervention	Months (Median)
Arm A (CLL)	3.0
Arm B (NHL)	5.3
Arm C (CLL With Richters)	3.0

The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

Treatment-free Survival of Patients Treated With Single-agent Pembrolizumab

Intervention	Months (Median)
Arm A (Continuation Phase)	7.7
Arm C (Continuation Phase)	3.2

The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier. (NCT02332980)
Timeframe: 5 years

Duration of Response (DoR): Study Cohort

Intervention	Months (Median)
Arm A (CLL)	2.7
Arm B (NHL)	4.6
Arm C (CLL With Richters)	2.9

DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and date of first documented evidence of progressive disease or death or date of censoring. iWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (>=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years 11 months

Duration of Stable Disease or Better: Study Cohort

Intervention	Months (Median)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	11.5
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	NA
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	19.2
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	10.2
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	NA
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg	6.9

Duration of stable disease or better was defined as duration from the start of the treatment until the criteria for progression were met. IWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years and 11 months

Overall Response Rate (ORR) as Assessed International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008: Disease Cohort

Intervention	Months (Median)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	24.8
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	20.8
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	17.38
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	14.55
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	14.1

ORR is percentage of participants achieving a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR) or PR. IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/L, platelets >100*10^9/L, Hgb >11 g/dL and absolute lymphocyte count <4000/mcL; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- >=50% drop in lymphocyte count from baseline or <=4.0*10^9/L with following: >=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, >=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils >1.5*10^9/L, Platelets>100000/mcL and Hgb>11 g/dL or >=50% improvement over baseline in all. This outcome measure was planned to be analyzed for specified arm only. (NCT02329847)
Timeframe: Up to 6 years 11 months

Overall Response Rate (ORR) as Assessed Non-Hodgkin Lymphoma (NHL), Cheson 2014: Disease Cohort

Intervention	Percentage of Participants (Number)
Ibrutinib and Nivolumab: Chronic Lymphocytic Leukemia (CLL)	63.3

ORR defined as percentage of participants achieving a CR, CRi, nPR or PR. As per Non-Hodgkin Lymphoma, Cheson 2014, CR is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is >= 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. Progressive disease (PD) >= 50% increase from nadir in the sum of the products of at least two lymph nodes, or appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. This outcome measure was planned to be analyzed for specified arms only. (NCT02329847)
Timeframe: Up to 6 years 11 months

Overall Survival (OS): Study Cohort

Intervention	Percentage of Participants (Number)
Ibrutinib and Nivolumab: Small Lymphocytic Lymphoma (SLL)	50.0
Ibrutinib and Nivolumab: Follicular Lymphoma (FL)	32.5
Ibrutinib and Nivolumab: Diffuse Large B-cell Lymphoma (DLBCL)	37.8
Ibrutinib and Nivolumab: Richter	65.0

OS was defined as duration from the date of first dose of study drug to the date of the participant's death. (NCT02329847)
Timeframe: Up to 6 years 11 months

Percentage of Participants With Lymphoma-related Symptoms: Study Cohort

Intervention	Months (Median)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	12.4
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	NA
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	NA
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	NA
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	19.0
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg	10.3

Percentage of participants with lymphoma-related symptoms were reported. These symptoms included B-symptoms, recurrent fever, night sweats, weight loss, other disease-related symptoms, itching, fatigue, physical discomfort and any other. (NCT02329847)
Timeframe: Up to 6 years 11 months

Percentage of Participants With Treatment-emergent Adverse Event (TEAEs): Study Cohort

Intervention	Percentage of Participants (Number)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	14.3
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	42.9
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	74.3
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	25.7
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	54.1
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg	60.0

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs for the treatment phase included events with an onset date/time on or after the start of study intervention through end of study were considered as treatment-emergent. (NCT02329847)
Timeframe: Up to 6 years 10 months

Progression-free Survival (PFS): Study Cohort

Intervention	Percentage of Participants (Number)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	100
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	100
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	100
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	100
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	97.3
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg	95.0

PFS is defined as the duration from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death, whichever comes first. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. IWCLL 2008 criteria for progressive disease: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; >= 50% increase from nadir in existing lymph node or >=50% increase from nadir in sum of product of diameters of multiple nodes; >=50% increase from nadir in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology. (NCT02329847)
Timeframe: Up to 6 years 11 months

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Intervention	Months (Median)
Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	2.0
Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	9.1
Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg	21.6
Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	7.6
Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg	3.2
Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg	5.0

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

Mean Change From Baseline to Cycle 5 in EORTC QLQ-C30 Global Health Status Score

Intervention	Participants (Count of Participants)
Ibrutinib Plus Rituximab	0

Mean change from baseline to Cycle 5 in the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) Global Health Status Score according to EORTC QLQ-C30 Scoring Manual (3rd Edition, 2001). For global health status, positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. A change in 5 to 10 points in either direction represents a small change; 10 to 20 points represents a moderate change and greater than 20 points represents a large change. (NCT01236391)
Timeframe: From Baseline to Cycle 5 (Week 20)

Number of Participants With Treatment Emergent Adverse Events (AEs)

Intervention	scores on a scale (Mean)
EORTC QLQ-C30	0.6

Number of participants who had experienced at least one treatment emergent AE (NCT01236391)
Timeframe: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure

PCI-32765 and Its Metabolite (PCI-45227) AUC0-24h After Repeat Dosing of PCI-32765

Intervention	participants (Number)
PCI-32765	111

Area under the plasma concentration-time curve using data collected at 0, 1, 2, 4, 6-8, and 24 hours post dose (AUC0-24h) (NCT01236391)
Timeframe: Performed During the First Month of Receiving PCI-32765

Percentage of Participants Achieving Response

Intervention	AUC0-24h (ng*h/mL) (Mean)
PCI-32765 - Day 8	953
PCI-45227 (Metabolite)- Day 8	1263

The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator. CR is a complete disappearance of all disease, no new lesions, lymph nodes must have regressed and be PET negative, spleen and liver should not be palpable and without nodules, and bone marrow must be negative. PR is a >/= 50% decrease in the sum of the product of diameters of the target lesions, and >/= 50% decrease of splenic and hepatic nodules from baseline, no new lesions and no increase in the size of liver, spleen or non-target lesions. (NCT01236391)
Timeframe: The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months

Food Effect Cohort Assessments

Intervention	percentage of participants with response (Number)
PCI-32765	67.6

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Number of Participants With Treatment Emergent Adverse Events (AEs)

Intervention	(Number)
Food Effect Cohort	1.65

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

Percentage of Participants Achieving Response

Intervention	Participants (Number)
PCI-32765	116
Food Effect	11

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

Progression Free Survival Rate at 24 Months

Intervention	Percentage of Participants (Number)
Treatment Naive	71
Relapsed/ Refractory	75.3
Food Effect	56.3

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

OS (Overall Survival)

Intervention	Percentage of Participants (Number)
Treatment Naive	96.3
Relapsed/ Refractory	73.6
Food- Effect	NA

OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up

Overall Response Rate (ORR) by Independent Review Committee (IRC)

Intervention	months (Median)
Ofatumumab (Arm A)	65.1
Ibrutinib (Arm B)	67.7

Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled

Overall Response Rate (ORR) by Investigator

Intervention	percentage of participants (Number)
Ofatumumab (Arm A)	4.1
Ibrutinib (Arm B)	42.6

Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

Intervention	percentage of participants (Number)
Ofatumumab (Arm A)	22.4
Ibrutinib (Arm B)	87.7

The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.

Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

Intervention	months (Median)
Ofatumumab (Arm A)	8.1
Ibrutinib (Arm B)	NA

Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Rate of Sustained Hemoglobin and Platelet Improvement

Intervention	months (Median)
Ofatumumab (Arm A)	8.1
Ibrutinib (Arm B)	44.1

Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Number of Participants With Treatment Emergent Adverse Events (AEs)

Intervention	percentage of participants (Number)
	Hgb Improvement in patient with baseline anemia	Platelet improvement in baseline thrombocytopenia
Ibrutinib (Arm B)	69.7	78.4
Ofatumumab (Arm A)	32.6	9.4

Number of participants who had experienced at least one treatment emergent AE (NCT01217749)
Timeframe: From first dose of study treatment to within 30 days of last dose or until study closure

Percentage of Participants Achieving Response

Intervention	participants (Number)
Group 1	27
Group 2	20
Group 3	24

The primary endpoint for the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR), CR with incomplete blood count recovery (Cri), or partial response (PR), according to the guidelines from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL1) published in 2008 for CLL participants and International Working Group for non-Hodgkin's lymphoma (IWG NHL) 2007 criteria for SLL participants, with the modification that treatment-related lymphocytosis will not be considered progressive disease, as evaluated by the investigators. Assessment of disease is based on radiological exams, physical exam, hematological evaluations and, when appropriate, bone marrow results. (NCT01217749)
Timeframe: The median follow-up time on study for all treated participants is 12.5 (range 0.5-19.6) months

Progression Free Survival (PFS) at 12 Months

Intervention	percentage of participants (Number)
Group 1	92.6
Group 2	80.0
Group 3	70.8

"Progressive disease for CLL (Hallek) is characterized by ≥1 of the following:~Appearance of any new lesion, eg lymph nodes (> 1.5 cm), de novo hepatomegaly or splenomegaly, or other organ infiltrates~Increase of ≥50%~in longest diameter of any previous site~in hepatomegaly or splenomegaly~in blood lymphocytes with ≥5x109/L B cells with enlarging lymph node, liver, or spleen~Progressive disease for B cell lymphoma (Cheson) is characterized by any new lesion or increase by ≥ 50% of previously involved sites from nadir:~Appearance of a new lesion(s) >1.5 cm in any axis, ≥ 50% increase in the SPD of >1 node, or ≥50% increase in longest diameter of a previously identified node >1 cm in short axis~Lesions PET+ if FDG-avid lymphoma or PET+ before therapy~50% increase from nadir in the SPD of any liver or spleen lesions~New or recurrent BM involvement~Increase of ≥50% in blood lymphocytes with ≥5x109/L B cells within enlarging lymph node, liver, or spleen" (NCT01217749)
Timeframe: From first dose of study treatment until disease progression, death, or until 12 months

Safety During Dose-Limiting Toxicity (DLT) Observation Period

Intervention	percentage of event free participants (Mean)
Group 1	88.7
Group 2	85.0
Group 3	75.0

Number of dose-limiting toxicities observed in the first 6 participants enrolled in treatment Groups 1 and 2 (NCT01217749)
Timeframe: 56 days for Group 1 and 28 days for Group 2

Cancer-Specific Stress as Measured by the Impact of Event Scale-Revised (IES-R)

Intervention	participants who experienced DLT (Number)
Group 1	0
Group 2	0

Cancer-Specific Stress was measured by the Impact of Event Scale-Revised Participants rated the intensity of these feelings using a five-point Likert scale ranging from 0=not at all to 4=extremely. Patients rated the frequency of their feelings or events for the previous week before treatment. The items were summed for a total score that ranged from 0 to 64 (NCT01589302)
Timeframe: Up to 2 years

Cognitive-Affective Depressive Symptoms as Measured by the Beck Depression Inventory-2nd Edition (BDI-II)

Intervention	units on a scale (Mean)
Treatment (Ibrutinib)	9.18

The Beck Depression Inventory-2nd edition is a 21-item measure of depressive symptoms. Scores were calculated representing the cognitive-affective and the somatic symptoms associated with depression (e.g. sadness, pessimism, loss of pleasure) during past month on scale from 0 to 3. Items were summed, with higher scores indicating more depressive symptoms. The scores on the scale from range from 0 to 42. (NCT01589302)
Timeframe: at 5 months

Effectiveness of Ibrutinib Bridging Patients to Allogeneic Stem Cell Transplant and Outcome of Patients Following This Intervention

Intervention	units on a scale (Mean)
Treatment (Ibrutinib)	1.88

The number of participants with successful Allogenic Stem Cell Transplant (NCT01589302)
Timeframe: Up to 2 years

Fatigue Symptom Inventory (FSI) Interference Quality of Life as Measured by a 11-item Total Disruption Index Sub Scale of Fatigue Symptoms Inventory

Intervention	participants (Number)
Treatment (Ibrutinib)	1

The Fatigue Interference quality of life measures is a 11-item self reported questionnaire used to measure frequency, severity and daily pattern of fatigue Symptoms as well as impact of QOL in the past week. The Total Disruption Index (TDI) an 7 item subset of FSI was used. Items were rated on a 11-point Likert scale from 0=no interference to 10=extreme interference. Total scores could range from 0 to 70, with higher scores indicating greater fatigue interference. (NCT01589302)
Timeframe: at 5 months

Mental Health Quality of Life Was Measured by the Mental Component Summary Score of the Medical Outcomes Study

Intervention	units on a scale (Mean)
Treatment (Ibrutinib)	9.70

SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning. (NCT01589302)
Timeframe: at 5 months

Negative Mood Quality of Life Measured by a 37-item Questionnaire

Intervention	units on a scale (Mean)
Treatment (Ibrutinib)	53.98

The Profile of Mood States-Short Form (POMS-SF) yields six subscales, Tension, Depression, Anger, Vigor, Fatigue, and Confusion. A total mood disturbance score is found by summing the six subscales. Total Mood Disturbance (TMD) scores range from -24 to 124 with higher scores indicating greater mood disturbance. (NCT01589302)
Timeframe: at 5 months

Physical Health Quality of Life as Measured by a 12 Item Short-Form Health Survey

Intervention	units on a scale (Mean)
Treatment (Ibrutinib)	0.89

Physical Health Quality of life measures were administered during screening and on Days 1 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru Cycle 24 and at time of progression and /or end of treatment. SF-12 assesses aspects of quality of life including physical functioning, role functioning-physical, bodily pain, general health perceptions, vitality, social functioning, role functioning-emotional, and mental health. Subscale raw scores are transformed to put each subscale on a 0-100 range with higher scores indicative of greater functioning. Subscale scores are standardized based on US General Population norms and aggregated based on factor score coefficients into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Component scores are norm-based t-scores meaning scores above 50 indicate better functioning than average functioning while scores below 50 indicate worse functioning. (NCT01589302)
Timeframe: up to 5 months

Resistance Studies of Ibrutinib

Intervention	units on a scale (Mean)
Treatment (Ibrutinib)	44.23

Percentage of patients with BTK C481S mutation or PLCG2 mutation (NCT01589302)
Timeframe: Up to 4 years

Sleep Through Quality of Life as Measured by a Medical Outcomes Study-Sleep Scale

Sleep problems quality of life measures is a six-item sleep problems index I of the Medical Outcomes Study-Sleep Scale used to assess sleep problems. Participants reported how often they experience six specific difficulties with sleep on a 6-point Likert scale (1=All of the time to 6=None of the time). Scores transformed into a 0-100 scale with higher scores indicating greater sleep problems. (NCT01589302)
Timeframe: at 5 months

2-year Kaplan-Meier Estimate of OS for Relapsed and Refractory CLL Patients Treated With Single Agent PCI-32765

Time from date of first treatment with ibrutinib until the date of progression or death from any cause. Those alive and progression free are censored at the date of last clinical assessment. (NCT01589302)
Timeframe: 2 years

Best Overall Response Rate Using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group Guidelines

Responders were subjects who achieved a complete response (CR), partial response (PR) or PR with persistent lymphocytosis. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01589302)
Timeframe: up to 2 years

Determine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL.

We will summarize our findings for this endpoint independently as well within each cohort (del17p vs other cytogenetic groups). We will evaluate the proportion of patients who are progression-free and alive at two years or have gone on to transplant (treatment successes) over the total number of evaluable patients; eligible patients who received at least one dose of therapy are considered evaluable. Assuming that the number of treatment successes as defined above is binomially distributed, we will also include 95% binomial confidence intervals for the estimates corresponding to each cohort. (NCT01589302)
Timeframe: up to 2 years

Number of Patients With 6 Month ORR of Single Agent Ibrutinib in Relapsed and Refractory CLL Patients

The 6 month overall response rates overall response rate (ORR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT01589302)
Timeframe: Up to 6 months

Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Adverse events grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 with the attribution of either definite, possible or probable related. (NCT01589302)
Timeframe: Up to 2 years post treatment

Percentage of Patients With Overall Survival (OS)

Time from date of first treatment with ibrutinib until the date of death from any cause or the date of last contact for those alive. (NCT01589302)
Timeframe: 2 years

Area Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss)

The AUC-ss is the area under the plasma concentration time curve observed during steady state. (NCT01646021)
Timeframe: Cycle 1 and 2 (Day 1): Predose, 1, 2, 4 hr. postdose; Cycle 3 (day 1): Predose (Each cycle is of 21 days)

Duration of Response

Duration of response (CR or PR), defined as the duration in days from the date of initial response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death. The analysis was based on the investigator assessment. (NCT01646021)
Timeframe: Approximately up to 48 months

Extent of Exposure of Time

Extent of exposure is defined as the duration of the treatment administered during the study. Duration of exposure is calculated as the number of months between the start and end of treatment. (NCT01646021)
Timeframe: Approximately up to 46.8 months

Number of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)

Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study. (NCT01646021)
Timeframe: Approximately up to 28.2 months

Number of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI)

Number of Participants Affected With Treatment-emergent Adverse Events

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT01646021)
Timeframe: Time from first dose of study drug until the last dose date + 30 days or the start of a subsequent anti-neoplastic therapy, whichever occur earlier (Approximately up to 4 years)

Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib

Biomarker evaluations to identify markers altering BCR signaling or activate alternative signaling pathways and explore their association with response or resistance to ibrutinib. Next-generation sequencing at baseline identifies possible primary resistance mutations and those found only at progression are acquired mutations on therapy. (NCT01646021)
Timeframe: Approximately up to 28.2 months

One Year Survival Rate

One -year survival rate, defined as the proportion of participants who were alive 1 year after randomization. (NCT01646021)
Timeframe: Month 12

Overall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved either CR or PR as best overall response based on the investigator assessment. CR is Disappearance of all target lesions while PR is greater than or equal to 30 % decrease in the sum of the longest diameter of target lesions and Overall Response (OR) is sum of CR and PR. (NCT01646021)
Timeframe: Approximately up to 48 months

Overall Survival (OS)

Overall survival (OS) was defined as the interval between the date of randomization and the date of death from any cause. (NCT01646021)
Timeframe: Approximately up to 48 months

Progression Free Survival (PFS)

PFS is defined as the duration in months from the date of randomization to the date of progression disease (PD) or relapse from complete response (CR) or death whichever was reported first and was assessed based on the investigator assessment. Revised Response Criteria for Malignant Lymphoma categorizes the response of the treatment of a patient's tumour to CR (the disappearance of all evidence of disease), Relapsed Disease or PD (Any new lesion or increase by greater than or equal to [>=] 50 percent [%] of previously involved sites from nadir). (NCT01646021)
Timeframe: Time from the date of randomization until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever occurred first (approximately 48 months)

Progression-Free Survival 2

Progression-free survival 2 defined as the time interval between the date of randomization and date of event, defined as progressive disease as assessed by investigator that started after the next line of subsequent anti-neoplastic therapy (including cross-over to ibrutinib), death from any cause, or the start of the second subsequent anti-neoplastic therapy if no progressive disease was recorded after the first subsequent anti-neoplastic therapy. (NCT01646021)
Timeframe: Approximately up to 48 months

Time to Response

Time to response for participants with CR/PR, defined as the interval between the date of randomization and date of initial documentation of response. (NCT01646021)
Timeframe: Approximately up to 2.8 years

Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)

Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life. (NCT01646021)
Timeframe: Approximately up to 48 months

Time-to-Next Treatment

Time to next treatment was measured from the date of randomization to the start date of any anti-neoplastic treatment subsequent to study treatment. (NCT01646021)
Timeframe: Approximately up to 48 months

Days of Hospitalization and Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)

The Mean Change From Baseline in Euro QoL Five-Dimension (EQ-5D-5L) Scores for Each Post Baseline Assessment

The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, using 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and possible total score range -0.594 to 1; higher score indicates a better health state. (NCT01646021)
Timeframe: Baseline, Cycle 2, 3, 4, 5, 6, 7, 8, 11, 14, 17, 20, 28, 36 and End of treatment (approximately up to 23 months)

DOR (Duration of Response)

The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

ORR (Overall Response Rate)

"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

Intervention	percent of patients (Number)
	All patients	Del(17p)	non-Del(17p)
Treatment (Ibrutinib)	69	66	72

Intervention	percentage of patients (Number)
	All patients	Del(17p)	non-Del(17p)
Treatment (Ibrutinib)	63	66	59

Intervention	patients (Number)
	All patients	Del(17p)	Non-del(17p)
Treatment (Ibrutinib)	63	66	59

Intervention	patients (Number)
	Anemia	Febrible Neutropenia	Leukocytosis	Atrial Fibrillation	Diarrhea	Gastric Hemorrhage	Gastrointestinal Disorders-other	Mucositis Oral	Nausea	Death	Edema Limb	Fatigue	General Disorders and Admin Site Conditions	Cholecystitis	Bronchial Infection	Infections and Infestations-other	Lung Infection	Otitis Media	Sepsis	Skin Infection	Urinary Tract Infection	Alanine Aminotransferase Increased	Blood Bilirubin Increased	Lymphocyte Count Decreased	Lymphocyte Count Increased	Neutrophil Count Decreased	Platelet Count Decreased	White Blood Cell Decreased	Hyperuricemia	Hypophosphatemia	Arthralgia	Arthritis	Hematuria	Hypoxia	Respiratory Failure	Rash Maculo-papular	Hematoma	Hypertension
Treatment (Ibrutinib)	13	2	18	1	2	1	1	1	2	1	1	1	2	1	1	4	10	1	2	2	1	1	1	14	54	40	8	10	4	1	2	1	2	1	1	1	1	7

Intervention	Days (Mean)
	Mean days of hospitalization	Mean days of emergency room visits
Ibrutinib	19.7	1.8
Temsirolimus	20.3	1.6

Intervention	Units on scale (Mean)
	Baseline	Change at Cycle 2	Change at Cycle 3	Change at Cycle 4	Change at Cycle 5	Change at Cycle 6	Change at Cycle 7	Change at Cycle 8	Change at Cycle 11	Change at Cycle 14	Change at Cycle 17	Change at Cycle 20	Change at Cycle 28	Change at Cycle 36	Change at End of treatment
Ibrutinib	0.7	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	0.0	0.0
Temsirolimus	0.7	0.0	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	-0.1	-0.1

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
Zanubrutinib for the treatment of Waldenström Macroglobulinemia. Expert review of hematology, 2020, Volume: 13, Issue:12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides	2020
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Annals of hematology, 2017, Volume: 96, Issue:7 Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Drug Therapy; Hematopoi	2017
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Expert opinion on drug safety, 2017, Volume: 16, Issue:9 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Humans; Leukemia, Lymp	2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. British journal of haematology, 2017, Volume: 179, Issue:3 Topics: Adenine; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines;	2017
Novel therapies for relapsed/refractory mantle cell lymphoma. Best practice & research. Clinical haematology, 2018, Volume: 31, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell;	2018
Chronic lymphocytic leukaemia. Lancet (London, England), 2018, 04-14, Volume: 391, Issue:10129 Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Di	2018
Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood, 2018, 08-16, Volume: 132, Issue:7 Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; L	2018
Prevention of hepatitis B virus reinfection in liver transplant recipients. Intervirology, 2014, Volume: 57, Issue:3-4 Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Liver;	2014
[Ibrutinib: A new drug of B-cell malignancies]. Bulletin du cancer, 2015, Volume: 102, Issue:6 Suppl 1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Chromosome Deletion; Genes, p53	2015
Treatment options for mantle cell lymphoma. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:16 Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation;	2015
Ibrutinib for mantle cell lymphoma. Future oncology (London, England), 2016, Volume: 12, Issue:4 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineoplastic Combine	2016
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. Clinical therapeutics, 2017, Volume: 39, Issue:1 Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disease-Free Survival; Humans; L	2017
[Is it possible to stop nucleos(t)ide analogue based therapy in chronic hepatitis B?]. Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:1 Pt 2 Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic	2008
[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab]. Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:5 Topics: Adenine; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody	2010
Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World journal of gastroenterology, 2010, May-28, Volume: 16, Issue:20 Topics: Adenine; Antiviral Agents; Asia; Guanine; Hepatitis B; Hepatitis B virus; Humans; Interferons; Lamiv	2010
Adenine phosphoribosyltransferase deficiency. Clinical journal of the American Society of Nephrology : CJASN, 2012, Volume: 7, Issue:9 Topics: Adenine; Adenine Phosphoribosyltransferase; Allopurinol; Animals; Biomarkers; Disease Progression; E	2012
High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013, Volume: 13, Issue:2 Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobul	2013
Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2003, Volume: 3, Issue:3 Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Transp	2003
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. Praxis, 2003, Aug-13, Volume: 92, Issue:33 Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B S	2003
Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. Clinics in liver disease, 2003, Volume: 7, Issue:3 Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivud	2003
[Management of chronic hepatitis B]. Praxis, 2005, Apr-20, Volume: 94, Issue:16 Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus;	2005
[Liver transplantation for complications of hepatitis B]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 2 Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combinati	2006
Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Annals of clinical microbiology and antimicrobials, 2006, Apr-06, Volume: 5 Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Humans; Immunoglobulins;	2006
[New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?]. Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:1 Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Transpl	2000
[Current knowledge on chronic hepatitis B therapy]. Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:4 Suppl Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B, Chronic; Humans; Interferon-alph	2001
2,8-dihydroxyadenine urolithiasis: report of a case first diagnosed after renal transplant. The Quarterly journal of medicine, 1988, Volume: 68, Issue:258 Topics: Adenine; Adenine Phosphoribosyltransferase; Adult; Female; Humans; Kidney Calculi; Kidney Failure, C	1988